| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font

Show document Help

Title:Completely resected stage III melanoma controversy : 15 years of national tertiary centre experience
Authors:ID Perić, Barbara (Author)
ID Milićević, Sara (Author)
ID Perhavec, Andraž (Author)
ID Hočevar, Marko (Author)
ID Žgajnar, Janez (Author)
Files:.pdf Peric-2021-Completely_resected_stage_III_melan.pdf (412,50 KB)
MD5: 122104E5650F3CF31AF0B359925B01D9
 
URL https://doi.org/10.2478/raon-2020-0056
 
Language:English
Work type:Scientific work
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Abstract:Background: Two prospective randomized studies analysing cutaneous melanoma (CM) patients with sentinel lymph node (SLN) metastases and rapid development of systemic adjuvant therapy have changed our approach to stage III CM treatment. The aim of this study was to compare results of retrospective survival analysis of stage III CM patients% treatment from Slovenian national CM register to leading international clinical guidelines. Patients and methods: Since 2000, all Slovenian CM patients with primary tumour % TIb are treated at the Institute of Oncology Ljubljana and data are prospectively collected into a national CM registry. A retrospective analysis of 2426 sentinel lymph node (SLN) biopsies and 789 lymphadenectomies performed until 2015 was conducted using Kaplan-Meier survival curves and log-rank tests. Results: Positive SLN was found in 519/2426 (21.4%) of patients and completion dissection (CLND) was performed in 455 patients. The 5-year overall survival (OS) of CLND group was 58% vs. 47% of metachronous metastases group (MLNM) (p = 0.003). The 5-year OS of patients with lymph node (LN) metastases and unknown primary site (UPM) was 45% vs. 21% of patients with synchronous LN metastasis. Patients with SLN tumour burden < 0.3 mm had 5-year OS similar to SLN negative patients (86% vs. 85%; p = 0.926). The 5-year OS of patients with burden > 1.0 mm was similar to the MLNM group (49% vs. 47%; p = 0.280). Conclusions: Stage III melanoma patients is a heterogeneous group with significant OS differences. CLND after positive SLNB might still remain a method of treatment for selected patients with stage III.
Keywords:cutaneous melanoma, surgery treatment, sentinel node biopsy, completion lymph node dissection, overall surviva
Publication status:Published
Publication version:Version of Record
Submitted for review:28.05.2020
Article acceptance date:24.07.2020
Publication date:08.10.2020
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
Year of publishing:2021
Number of pages:Str. 50-56
Numbering:Letn. 55, Št. 1
PID:20.500.12556/DKUM-90927 New window
UDC:616.5
ISSN on article:1318-2099
COBISS.SI-ID:32786435 New window
DOI:10.2478/raon-2020-0056 New window
Publication date in DKUM:08.10.2024
Views:122
Downloads:10
Metadata:XML DC-XML DC-RDF
Categories:Misc.
:
Copy citation
  
Average score:(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share



Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Licences

License:CC BY-NC-ND 3.0, Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported
Link:http://creativecommons.org/licenses/by-nc-nd/3.0/
Description:You are free to reproduce and redistribute the material in any medium or format. You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Licensing start date:08.10.2020

Secondary language

Language:Slovenian
Keywords:kožni melanom, kirurško zdravljenje, biopsija varovalne bezgavke, popolna disekcija bezgavk, splošno preživetje


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica